All Oncology News

The baseline characteristics, treatment patterns, and responses to first-line platinum-based chemotherapy for patients with locally advanced or metastatic urothelial carcinoma receiving avelumab maintenance therapy were consistent with responses to usual therapy paradigms in the first-line induction setting.

The efficacy profile for avelumab in patients with locally advanced or metastatic urothelial carcinoma was consistent in a real-world setting with what had been reported in the phase 3 JAVELIN Bladder 100 trial.

Tiffany A. Traina, MD, discusses the significance of the FDA approval of sacituzumab govitecan for patients with metastatic hormone receptor-positive, HER2-negative breast cancer and expanded on the data from TROPiCS-02 that supported the approval.

Al-Ola A. Abdallah, MD, discusses updated safety and efficacy data with HPN217 in relapsed/refractory multiple myeloma and next steps for the investigation as well as sequencing of BCMA-targeted therapies for this patient population.

Florida Cancer Specialists & Research Institute, LLC is pleased to announce that Hitesh Patel, MD has joined its Executive Board, effective January 27, 2023.

An increasing focus on antibody-drug conjugates for HER2-positive breast cancer signals a potential shift in the standard of care for this population.

Trauma and stress related to the COVID-19 pandemic, coupled with subsequent widespread labor shortages, have turned burnout, which was an endemic issue in medicine, to a pandemic in health care.

Shubham Pant, MD, MBBS, discusses significant efficacy and safety data from the RAGNAR trial, how erdafitinib fits into the current treatment paradigm for biliary tract cancers, and the role of next-generation sequencing in the selection of FGFR inhibitors for this patient population.

High initial complete remission with or without platelet recovery, as well as an improvement in durable complete remission was achieved with the use of Iomab-B-based conditioning prior to allogeneic hematopoietic cell transplantation compared with conventional care in older patients with relapsed/refractory acute myeloid leukemia.

The addition of vedolizumab added to standard prophylaxis following unrelated allogeneic hematopoietic stem cell transplantation was superior to placebo at preventing lower gastrointestinal acute graft-vs-host disease.

Second infusion with tisagenlecleucel after prior tisagenlecleucel infusion produced short durations of minimal residual disease-negative responses in children and young adults with B-cell acute lymphoblastic leukemia.

The combination of nivolumab and cabozantinib produced prolonged progression-free survival and higher response rates compared with sunitinib alone as frontline therapy in patients with advanced renal cell carcinoma, regardless of International Metastatic RCC Database Consortium risk status.

Idecabtagene vicleucel demonstrated a statistically significant and clinically meaningful improvement in progression-free survival and objective response compared with standard of care approaches in patients with triple-class-exposed relapsed/refractory multiple myeloma.

89Zr-DFO-girentuximab demonstrated sensitivity and specificity thresholds that were exceeded by 3 independent readers for PET/CT imaging of clear cell renal cell carcinoma, according to findings from the phase 3 ZIRCON study.

The combination of frontline cabozantinib, nivolumab, and ipilimumab led to a greater improvement in progression-free survival in patients with intermediate- vs poor-risk advanced renal cell carcinoma.

Patients with multiple myeloma who were treated with autologous stem cell transplantation were found to be utilizing chronic opioids at high rates, in turn leading to worse overall survival outcomes at 6 months of follow-up.

Treatment with cabozantinib elicited responses in patients with locally advanced or metastatic renal cell carcinoma with a clear-cell component who had progressed after first-line treatment with checkpoint inhibitor–based combination therapy.

Treatment with the cellular therapy Orca-T produced an improved graft-vs-host-disease and relapse-free survival rate in patients with high-risk myelodysplastic syndrome or acute leukemias.

First-line atezolizumab plus platinum-based chemotherapy and gemcitabine trended toward improved overall survival compared with placebo plus chemotherapy in patients with locally advanced or metastatic urothelial carcinoma.

At extended follow-up, nivolumab monotherapy showed improved disease-free survival, non-urothelial tract recurrence-free survival, and disease-specific survival vs placebo in patients with resected, high-risk muscle-invasive urothelial carcinoma.

Atezolizumab monotherapy failed to show an improvement in overall survival compared with placebo plus platinum-based chemotherapy and gemcitabine in patients with untreated locally advanced or metastatic urothelial cancer.

Pembrolizumab monotherapy led notable antitumor activity with manageable toxicity in patients with Bacillus Calmette-Guérin–unresponsive, papillary high-risk non–muscle-invasive bladder cancer

The PARP inhibitor rucaparib improved median radiographic progression-free survival by 4.8 months compared with physician’s choice of therapy for men with BRCA-altered metastatic castration-resistant prostate cancer.

The combination of niraparib, abiraterone acetate, and prednisone produced prolonged survival and delayed progression rates in patients with metastatic castration-resistant prostate cancer harboring homologous recombination repair gene alterations.

Radium-223 demonstrated efficacy with low rates of treatment-related adverse effects and treatment discontinuation in patients with metastatic castration-resistant prostate cancer that metastasized to the bones.

Treatment with the anti–Trop-2 antibody-drug conjugate sacituzumab govitecan elicited an objective response rate of 32% in platinum-ineligible patients with metastatic urothelial cancer following progression on an immune checkpoint inhibitor, according to the primary analysis of TROPHY-U-01 cohort 2.

Tumor mutational burden and alterations in CDKN2A, CDKN2B, and MTAP were among several biomarkers that were predictive of response to enfortumab vedotin in patients with advanced urothelial carcinoma, according to findings from a retrospective analysis.

Because of an economic burden on the healthcare system occurring through the per-patient cost of allogeneic hematopoietic cell transplant, novel treatments to replace transplant and prevent graft-vs-host disease are necessary.

The presence of cytopenias did not affect the favorable and durable responses seen with ruxolitinib vs best available therapy in patients with steroid-refractory acute graft-vs-host disease.

Transurethral resection of bladder tumor followed by gemcitabine, cisplatin, and nivolumab led to stringent clinical complete responses in patients with muscle-invasive bladder cancer.